Építés alatt – nem éles oldal
Belépés

NCT06591013Befejeződött

Efficacy and Mechanism of Fecal Microbiota Transplantation of the Bai Ethnicity in the Treatment of UC

Research on the Mechanisms of Different Donors in Fecal Microbiota Transplantation for Treating Ulcerative Colitis

Forrás: ClinicalTrials.gov · Utoljára frissítve: 2026. jún. 30.

Következő lépések

Rövid összefoglaló (regiszter, angolul)

Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), affects over 2 million people worldwide . Although biological therapies have significantly improved the treatment outcomes for UC, nearly two-thirds of patients experience diminishing drug responses over time, making it crucial to explore novel therapeutic approaches targeting the underlying pathophysiology of UC. UC is associated with alterations in gut microbiota, reduced microbial diversity, and changes in the relative abundance of dominant bacterial populations. Specifically, UC patients exhibit a marked decrease in gut microbiota diversity at the species level, with a reduction in Firmicutes (e.g., Clostridium butyricum) and an increase in Actinobacteria, Proteobacteria (e.g., Escherichia coli), Enterobacteriaceae, Streptococcus, and Bacteroides . Given the association between gut microbiota alterations and IBD activity, several studies have proposed microbiota-based therapies, particularly fecal microbiota transplantation (FMT), as a treatment for UC.

Állapot (regiszter)
Befejeződött
Vizsgálattípus
Beavatkozással járó
Résztvevők száma
102 (tényleges)
Első benyújtás
2024. júl. 17.
Kezdés
2024. okt. 14.
Elsődleges befejezés
2025. okt. 20.
Fő szponzor
First Affiliated Hospital of Kunming Medical University
Betegségek
Colitis ulcerosa
NCT-szám
NCT06591013

Mit vállalsz

  • Vizsgálat típusa: Beavatkozással járó
  • Bevont résztvevők: 102
  • 2024. okt. 14. és az elsődleges befejezés (2025. okt. 20.) között
  • 1 helyszín, 1 országban
  • Vizitek és vizsgálatok: kérdezd a vizsgálat csapatát, a regiszter nem sorolja fel őket

A(z) ClinicalTrials.gov regisztermezőiből összeállítva. A vizsgálat felépítését írja le.

Ki nem vehet részt

Szó szerint a(z) ClinicalTrials.gov forrásból, témák szerint csoportosítva. Hogy ki vehet részt, azt csak a vizsgálat csapata dönti el.

Korábbi kezelés

  • Steroid dependence requiring >20 mg prednisone or >9 mg budesonide daily at enrollment.
  • Recent or anticipated usage of prohibited drugs during the study period, including:
    • Rectal corticosteroids within 2 weeks prior to the first FMT.
    • Biologics (e.g., infliximab, adalimumab, vedolizumab) within 4 weeks prior to the first FMT.
    • Other major immunosuppressants (e.g., calcineurin inhibitors, antitumor drugs) within 12 weeks prior to treatment.
    • Probiotics within 4 weeks before the first FMT.
    • Experimental drugs or protocols within 12 weeks before the first FMT.
    • Anti-tuberculosis (TB or MAC) treatment within 4 weeks before the first FMT.
    • Permitted Medications:
    • Participants may continue using the following medications if doses are stable within specified timeframes before the first FMT:
  • Oral prednisone (≤20 mg/day, stable for 2 weeks, gradually tapered at a rate of 2.5 mg/week to discontinue by week 8).
    • Subjects should maintain the same doses of oral 5-aminosalicylates, thiopurines, and methotrexate during the study. For oral prednisolone, the dose had to be tapered off gradually, at a rate of 2.5mg per week, so that subjects were no longer exposed to steroids until week 8.
    • Prohibited Medications:
  • Rectal corticosteroids (2 weeks before and throughout the study).
  • Antibiotics, antifungals, antivirals, probiotics, or prebiotics (4 weeks before and throughout the study).
  • Biologics or calcineurin inhibitors (12 weeks before and throughout the study). Participants using prohibited medications during the study will remain enrolled, and outcomes will still be evaluated. All prohibited medication usage will be recorded.

Más betegség

  • Evidence or history of toxic megacolon.
  • Diagnosed with Crohn's disease or indeterminate colitis.
  • Participants with perianal diseases (e.g., fistulae, anal fissures).
  • History of significant gastrointestinal surgery (e.g., colectomy) :
    • Minor surgeries will be reviewed case by case.
    • Patients with appendectomy within 3 months will be excluded.

Egyéb

  • Participants unable to provide informed consent, answer questionnaires, or supply samples.
  • Pregnant women or those attempting to conceive.
  • Participants unwilling to use effective contraception throughout the study.
  • Participants deemed in remission by investigators.
  • Isolated rectal inflammation (<5 cm in extent).
  • Antibiotic use within the past 4 weeks for any reason, including for UC.
  • Oral 5-aminosalicylic acid (stable for 4 weeks).
  • Azathioprine and methotrexate (≥90 days of use with stable doses for 4 weeks).

Kiket keres a vizsgálat

  • Age between 14 and 79 years (inclusive), any gender.
  • Diagnosed with ulcerative colitis (UC) per established clinical, endoscopic, and histological standards, with a disease duration of over 3 months.
  • Active mild-to-moderate UC, defined by a Mayo score of 4-10, including an endoscopic score ≥1 and a physician's global assessment score ≤2.
  • Stable baseline medication consisting of 5-aminosalicylic acid (mesalamine).
  • Signed written informed consent.

Életkor a regiszterben: 14 év – 79 év · Nem: nők és férfiak · Egészséges önkénteseket nem fogad

A teljes feltétellista: ClinicalTrials.gov

Helyszínek (1)

Helyszínek a regiszter sorrendjében. Ha a profilodba mented a városodat, távolság szerint rendeződnek.

HelyszínVárosOrszágHelyszín állapota
ChinaKunmingKínaIsmeretlen állapot

Te vagy a koordinátor? Erősítsd meg az adatokat

Ez az oldal tájékoztatás, nem orvosi tanács. Bármely vizsgálatról az orvosoddal beszélj.